Online citations, reference lists, and bibliographies.
← Back to Search

Impact Of APOE Genotype On Neuropathologic And Neurochemical Markers Of Alzheimer Disease

P. Tiraboschi, L. Hansen, E. Masliah, M. Alford, L. Thal, J. Corey-Bloom
Published 2004 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Background: The APOE ε4 allele has emerged as a major genetic factor for Alzheimer disease (AD), and its presence has been associated with an increase in β-amyloid senile plaques (SPs) and neuritic plaques (NPs). Whether it affects neurofibrillary tangle (NFT) accumulation or cholinergic losses in AD remains controversial. In contrast, the ε2 allele has been reported to decrease the risk for AD. However, its effect on neuropathologic and neurochemical markers of disease is unclear. Objective: To investigate the relationship between APOE genotype and both pathologic severity and cholinergic dysfunction in AD. Methods: In an autopsy series of 296 patients with AD, APOE genotype was determined in blood or postmortem brain tissue. NPs and NFTs were counted in the midfrontal (MF), inferior parietal (IP), and superior temporal (ST) cortices and the hippocampus. Choline acetyltransferase (ChAT) activity was assessed in the MF, IP, and ST cortices. Results: Compared with patients with no ε4 alleles, ε4 carriers (patients with either one or two ε4 alleles) did not differ significantly with regard to any pathologic or neurochemical measures, except for increased ST NPs. However, when cases were stratified into three groups according to the number of ε4 alleles, patients with two ε4 alleles had significantly more NPs and NFTs in all neocortical regions than those with either one or no ε4 alleles. The association of the ε4/4 genotype with neocortical pathologic severity remained significant even after adjusting for age at onset or age at death. In contrast, there were no significant group differences with regard to neocortical ChAT activity. When pathologic and neurochemical measures were compared between patients with the ε2 allele and those without, a strong relationship emerged between the ε2 allele and decreased NPs in all neocortical regions. Conclusions: The ε4 allele does not predict cholinergic decline in AD. Although the presence of a single ε4 allele appears to have no effect, the presence of two ε4 alleles is an important determinant of both NP and NFT accumulation. A putative protective role for the ε2 allele in AD may be mediated by reduced plaque burden.
This paper references
10.1111/j.1471-4159.1975.tb11895.x
A rapid radiochemical method for the determination of choline acetyltransferase
F. Fonnum (1975)
10.1002/ANA.410100209
Some morphometric aspects of the brain in senile dementia of the alzheimer type
R. Terry (1981)
Clinical and pathological correlates of apolipoprotein E e4 in Alzheimer’s disease
T Gomez-Isla (1982)
10.1212/WNL.34.7.939
Clinical diagnosis of Alzheimer's disease
G. Mckhann (1984)
Diagnosis of Alzheimer's disease.
C. Filley (1988)
10.1212/WNL.38.1.48
Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimer's disease
L. Hansen (1988)
[Clinical diagnosis of Alzheimer's disease].
A. Kurz (1988)
10.1212/WNL.41.4.479
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
S. S. Mirra (1991)
10.1016/0140-6736(91)92823-K
Apolipoprotein E genotyping by one-stage PCR
P. Wenham (1991)
10.1016/0006-8993(91)91092-F
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease
Y. Namba (1991)
10.1073/PNAS.90.5.1997
Evolution of maize inferred from sequence diversity of an Adh2 gene segment from archaeological specimens.
P. Goloubinoff (1993)
10.1073/PNAS.90.5.1977
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
W. Strittmatter (1993)
10.1016/0896-6273(93)90070-8
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
G. W. Rebeck (1993)
10.1073/PNAS.90.20.9649
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.
D. Schmechel (1993)
10.1126/SCIENCE.8346443
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
E. Corder (1993)
10.1038/NG0694-180
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
E. Corder (1994)
10.1006/exnr.1994.1019
Hypothesis: Microtubule Instability and Paired Helical Filament Formation in the Alzheimer Disease Brain Are Related to Apolipoprotein E Genotype
W. Strittmatter (1994)
Apolipoprotein E type 2 allele decreases the risk of late-onset Alzheimer disease
EH Corder (1994)
10.1016/0304-3940(94)12126-B
Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians
C. Morris (1995)
10.1016/0304-3940(95)11343-6
A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele
H. Soininen (1995)
10.1016/0306-4522(95)00331-C
Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease
Z. Nagy (1995)
10.1056/NEJM199511093331902
Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.
T. Polvikoski (1995)
10.1016/0306-4522(94)00596-W
Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation
T. Ohm (1995)
10.1073/PNAS.92.26.12260
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.
J. Poirier (1995)
10.1016/0197-4580(95)00076-Q
Alzheimer pathology of patients carrying apoliprotein E ϵ4 allele
O. Heinonen (1995)
Apolipoprotein 4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer’s disease
J Poirier (1995)
10.1097/00005072-199603000-00013
Neurons of the Human Frontal Cortex Display Apolipoprotein E Immunoreactivity: Implications for Alzheimer's Disease
R. Metzger (1996)
10.1212/WNL.47.1.190
The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant
J. Olichney (1996)
10.3233/JAD-2006-9S347
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
I. McKeith (1996)
10.1097/00005072-199601000-00005
Neocortical Lewy Body Counts Correlate with Dementia in the Lewy Body Variant of Alzheimer's Disease
W. Samuel (1996)
10.1002/ANA.410390110
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
T. Gómez-Isla (1996)
10.1016/0022-510X(96)00008-1
Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients
D. Sparks (1996)
10.1007/978-3-7091-6892-9_14
Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias.
C. Morris (1996)
10.1136/jnnp.61.4.352
The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease.
M. Landén (1996)
10.1111/j.1365-2990.1997.tb01325.x
Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease
T. Dickson (1997)
10.1016/S0304-3940(97)00872-0
Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype
S. Allen (1997)
10.1016/S0304-3940(97)00573-9
Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes
A. Svensson (1997)
10.1001/ARCHNEUR.55.3.326
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.
L. Berg (1998)
10.1001/archneur.55.3.326
Clinicopathologic studies in cognitively healthy aging and Alzheimer disease
L. Berg (1998)
10.1007/s004010051080
Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions
T. Ohm (1999)
10.1212/WNL.56.12.1696
Gender and age modify the association between APOE and AD-related neuropathology
E. Ghebremedhin (2001)
10.1016/S0169-328X(02)00647-2
Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques.
Mark P Burns (2003)
10.1046/j.1365-2990.2003.00425.x
Tau load is associated with apolipoprotein E genotype and the amount of amyloid β protein, Aβ40, in sporadic and familial Alzheimer's disease
U. Thaker (2003)
10.1212/01.WNL.0000042478.08543.F7
Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer’s disease
D. Bennett (2003)
10.1007/BF00308809
Neuropathological stageing of Alzheimer-related changes
H. Braak (2004)



This paper is referenced by
10.1093/braincomms/fcab126
Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
Yi‐Ting Wang (2021)
10.1002/glia.24105
Microglia-specific ApoE knock-out does not alter Alzheimer's disease plaque pathogenesis or gene expression.
Caden M Henningfield (2021)
10.1007/s00259-021-05192-8
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
G. Salvadó (2021)
10.3233/JAD-201005
Fine Particulate Matter and Markers of Alzheimer's Disease Neuropathology at Autopsy in a Community-Based Cohort.
R. Shaffer (2021)
10.1186/s40478-021-01204-8
CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia
C. Lodder (2021)
10.31083/j.jin2002027
Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-β in mild cognitive impairment but not in Alzheimer's disease.
Feng Xing (2021)
10.1111/bpa.13016
Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease.
J. Camacho (2021)
10.3389/fnagi.2021.591347
Effects of APOE ε2 on the Fractional Amplitude of Low-Frequency Fluctuation in Mild Cognitive Impairment: A Study Based on the Resting-State Functional MRI
Xiaocao Liu (2021)
10.3390/ijms22073330
Alzheimer’s Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia
M. Eshraghi (2021)
10.1186/s13195-020-00712-4
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review
Sheina Emrani (2020)
10.3233/ADR-200250
Porphyromonas gingivalis is a Strong Risk Factor for Alzheimer’s Disease
S. Kanagasingam (2020)
10.1016/j.arr.2020.101126
From beta amyloid to altered proteostasis in Alzheimer’s disease
A. Bruni (2020)
10.1186/s13024-020-0358-9
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Tosha Williams (2020)
10.1038/s41380-020-0824-3
MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer’s disease pathogenesis
(2020)
10.1186/s13195-020-00710-6
Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease
Min Seok Baek (2020)
10.1101/2020.12.03.20241851
Age, sex and APOE-ϵ4 modify the balance between soluble and fibrillar β-amyloid in cognitively intact individuals: topographical patterns and replication across two independent cohorts
R. Cacciaglia (2020)
10.1038/s41380-020-0688-6
APOEε4 potentiates the relationship between amyloid-β and tau pathologies
Joseph Therriault (2020)
10.7150/thno.48522
Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer's disease
Shaozhen Yan (2020)
10.3389/fnagi.2020.00046
Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β-amyloid, Tau, and APOE4
F. Quevenco (2020)
10.1007/978-981-32-9721-0_3
Genetic Markers of Alzheimer's Disease.
M. Nikolac Perkovic (2020)
10.1161/JAHA.118.011146
Apolipoprotein E Genotype Modifies the Association Between Cardiac Output and Cognition in Older Adults
Corey W. Bown (2019)
asis for Apolipoprotein E 4 k Factor for Late-Onset ase oussra
Ana-Caroline Raulin (2019)
10.1016/j.jmb.2019.04.019
The Molecular Basis for Apolipoprotein E4 as the Major Risk Factor for Late-Onset Alzheimer's Disease
Ana-Caroline Raulin (2019)
10.1177/1759091419845524
Higher Level of Mismatch in APOE ε4 Carriers for Amyloid-Beta Peptide Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid
Jonathan Vogelgsang (2019)
10.1016/j.cca.2019.02.005
Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits.
C. Bouter (2019)
Mechanisms of Microglia Mediated Apolipoprotien E Neurotoxicity
Pardeep Singh (2019)
10.3389/fneur.2019.01303
Association Between Hippocampus, Thalamus, and Caudate in Mild Cognitive Impairment APOEε4 Carriers: A Structural Covariance MRI Study
F. Novellino (2019)
10.3233/jad-190464
Impact of APOE and BDNF Val66Met Gene Polymorphisms on Cognitive Functions in Patients with Amnestic Mild Cognitive Impairment.
K. Cechová (2019)
Clinical and genetic heterogeneity in young onset sporadic Alzheimer's disease
C. Slattery (2019)
10.1038/s41582-019-0228-7
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yu Yamazaki (2019)
10.3389/fnagi.2019.00233
Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities
A. Hemonnot (2019)
10.1038/s41392-019-0063-8
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Pei-pei Liu (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar